Journal
ACTA BIOCHIMICA ET BIOPHYSICA SINICA
Volume 46, Issue 3, Pages 240-253Publisher
OXFORD UNIV PRESS
DOI: 10.1093/abbs/gmt142
Keywords
immunomodulatory drugs; multiple myeloma; cancer treatment; cereblon; E3 ubiquitin ligase
Categories
Funding
- Leukemia & Lymphoma Society (LLS)
Ask authors/readers for more resources
Although immunomodulatory drugs (IMiDs), such as thalidomide, lenalidomide, and pomalidomide, are widely used in the treatment of multiple myeloma (MM), the molecular mechanism of IMiDs' action is largely unknown. In this review, we will summarize recent advances in the application of IMiDs in MM cancer treatment as well as their effects on immunomodulatory activities, anti-angiogenic activities, intervention of cell surface adhesion molecules between myeloma cells and bone marrow stromal cells, anti-inflammatory activities, anti-proliferation, pro-apoptotic effects, cell cycle arrest, and inhibition of cell migration and metastasis. In addition, the potential IMiDs' target protein, IMiDs' target protein's functional role, and the potential molecular mechanisms of IMiDs resistance will be discussed. We wish, by presentation of our naive discussion, that this review article will facilitate further investigation in these fields.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available